Business
Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and Scientific Conference hosted by the Kennedy's Disease Association (KDA). Held between February 27 and March 2, the conference served as a premier forum bringing together patients with Spinal and Bulbar Muscular Atrophy (SBMA), caregivers, clinicians and leading researchers to discuss advances in disease science, therapeutic development, and clinical care.
About this update from Annji Pharmaceutical Co., Ltd.
[{"type":"text","content":"TAIPEI, March 4, 2026 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and Scientific Conference hosted by the Kennedy's Disease Association (KDA). Held between February 27 and March 2, the conference served as a premier forum bringing together patients with Spinal and Bulbar Muscular Atrophy (SBMA), caregivers, clinicians and leading researchers to discuss advances in disease science, therapeutic development, and clinical care.","length":516,"tagName":"p"},{"type":"image","alt":"Dr. Wendy Huang, CEO and Chairperson of AnnJi, hosts the "Patient & Family Forum" at the 2026 KDA Conference. By engaging in deep dialogue regarding lived expertise and clinical care with the global SBMA community, this initiative strengthens patient-provider connections and bolsters international confidence in AJ201’s clinical development. (PRNewsfoto/AnnJi Pharmaceutical Co., Ltd.)","displaySize":"","headline":null,"caption":"Dr. Wendy Huang, CEO and Chairperson of AnnJi, hosts the \"Patient & Family Forum\" at the 2026 KDA Conference. By engaging in deep dialogue regarding lived expertise and clinical care with the global SBMA community, this initiative strengthens patient-provider connections and bolsters international confidence in AJ201’s clinical development. (PRNewsfoto/AnnJi Pharmaceutical Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":259,"url":"https://media.zenfs.com/en/prnewswire.com/c26c1e0ac3f8e00373827fab24163b48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7Gg7WVeoSzVTFJBCm5eMEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c26c1e0ac3f8e00373827fab24163b48","width":400,"height":259}},"href":"https://mma.prnewswire.com/media/2926652/Dr__Wendy_Huang_hosts_the_Patient___Family_Forum_at_the_2026_KDA_Conference.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Building on the recent U.S. FDA Fast Track Designation for AJ201(Rosolutamide) and encouraging Phase 2 clinical results, AnnJi presented two scientific abstracts spanning translational transcriptomic findings through highly anticipated Phase 3 trial. These presentations underscored AJ201's multi-modal mechanism of action and its potential as a first-in-c...